About DNA excision repair protein ERCC-8
DNA excision repair protein ERCC-8 (ERCC8) is a protein
from Homo sapiens identified by UniProt accession
Q13216, 396 residues long.
MolForge cross-references it against 0 known binders and
119 disease associations.
Target properties
| Protein name | DNA excision repair protein ERCC-8 |
| UniProt accession | Q13216 |
| Gene | ERCC8 |
| Organism | Homo sapiens |
| Length | 396 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (119)
Diseases linked to this target (Open Targets).
- Cockayne syndrome type 1 · score 0.85
- Cockayne syndrome · score 0.72
- UV-sensitive syndrome 2 · score 0.67
- UV-sensitive syndrome · score 0.55
- genetic disorder · score 0.47
- Cockayne syndrome type 2 · score 0.37
- Cockayne syndrome type 3 · score 0.37
- Abnormality of the nervous system · score 0.27
- hearing loss, autosomal recessive · score 0.27
- Parkinson disease · score 0.24
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q13216-F1 | alphafold | PREDICTED | 91.61 | — |
Amino-acid sequence (396 residues)
MLGFLSARQT GLEDPLRLRR AESTRRVLGL ELNKDRDVER IHGGGINTLD IEPVEGRYML SGGSDGVIVL YDLENSSRQS YYTCKAVCSI GRDHPDVHRY SVETVQWYPH DTGMFTSSSF DKTLKVWDTN TLQTADVFNF EETVYSHHMS PVSTKHCLVA VGTRGPKVQL CDLKSGSCSH ILQGHRQEIL AVSWSPRYDY ILATASADSR VKLWDVRRAS GCLITLDQHN GKKSQAVESA NTAHNGKVNG LCFTSDGLHL LTVGTDNRMR LWNSSNGENT LVNYGKVCNN SKKGLKFTVS CGCSSEFVFV PYGSTIAVYT VYSGEQITML KGHYKTVDCC VFQSNFQELY SGSRDCNILA WVPSLYEPVP DDDETTTKSQ LNPAFEDAWS SSDEEG
Explore DNA excision repair protein ERCC-8 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets